Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer.

ABSTRACT: Diversity in the genetic lesions that cause cancer is extreme. In consequence, a pressing challenge is the development of drugs that target patient-specific disease mechanisms. To address this challenge, we employed a chemistry-first discovery paradigm for de novo identification of druggable targets linked to robust patient selection hypotheses. In particular, a 200,000 compound diversity-oriented chemical library was profiled across a heavily annotated test-bed of >100 cellular models representative of the diverse and characteristic somatic lesions for lung cancer. This approach led to the delineation of 171 chemical-genetic associations, shedding light on the targetability of mechanistic vulnerabilities corresponding to a range of oncogenotypes present in patient populations lacking effe

SUBMITTER: McMillan EA 

PROVIDER: S-EPMC5935540 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature